Behind the Creative…Inspiring Award Winning Creative with John England
June 8th 2022CDM Princeton’s Senior Creative Vice President John England discuss the company’s APEX-award winning Ilumya campaign “Defy the Laws of Psoriasis,” which used multiple innovative ideas including an AR focused in-person interactive piece, a upward scrolling website and more.
New Guidance For Biopharma Investor ESG Communications
May 26th 2022Myrto Kontaxi, a partner in the Biopharma Sustainability Roundtable, and lead author on its updated Biopharma Investor ESG Communications Guidance; and Victoria Emerick, global head of sustainability strategy and operations at Bristol Myers Squibb, a Biopharma Sustainability Roundtable participant, and a key contributor to the Guidance development process, discuss the growing demand for better communication about ESG strategy and performance, and how the updated ESG Guidance can help both biopharma companies and investors respond.
Behind the Creative...Inspiring Award Winning Creative with Cindy Machles and Nate Whipple
May 25th 2022Glue Advertising's Cindy Machles, CEO and Co-founder & Nate Whipple, Producer, discuss their APEX-award winning respiratory campaign "For My Lung Health" delivered through videos, SEM, and a website--in English and Spanish--as an educational initiative by ATS and CHEST to inform people of color about lung health.
Patient Safety Needs Modernization. Now
May 20th 2022In this podcast, co-founder and CTO of Emulate, Inc, discusses why now is the time for researchers to accelerate their transition from animal models to human relevant-science with Organ-on-chip technology. There is no doubt that animal models have contributed to major advances in medicine, however, a growing body of evidence suggests that animal models are seriously lacking in both sensitivity and specificity when it comes to predicting drug toxicity in humans. In a recent study published to bioRxiv, researchers found the human Liver-Chip to have an 87% sensitivity and 100% specificity when differentiating hepatotoxic from non-hepatotoxic small molecules. Importantly, all 22 hepatotoxic drugs included in the study had previously been classified as safe due to a lack of toxicity in animal models. Collectively, these compounds resulted in 208 patient fatalities and 10 liver transplants. Had the human Liver-Chip been used during preclinical screening of these compounds, it’s likely that many of these fatalities could have been avoided. By adopting organ-on-a-chip, you can help make the drug development process safer, more efficient and more humane.
Behind the Creative...Inspiring Award Winning Creative with Troy Clark and Anne Brown
May 11th 2022Biolumina's Troy Clark, SVP, Creative Director, and Anne Brown, SVP, Creative Director, Copy discuss their APEX-award winning website "Be in the Know" for AstraZeneca's metastatic non-small cell lung cancer (NSCLC) disease state education efforts.
Price Transparency Regulations are Accelerating Market Disruption. Are You Prepared?
February 11th 2022As pricing transparency regulations and COVID-19 accelerate market disruption and changes in consumer behavior demand new engagement models, how can your organization prepare for the powerful shift toward more consumer-centric pricing transparency?
How Advanced Analytics Transforms Pharma Data into Actionable Insight
October 1st 2021Go beyond the hype of digital transformation and learn its true promise. With advanced analytics in your pharma labs, you can transform all your data into actionable scientific and business insights that lead to better outcomes. LabVantage Solutions is working with pharmaceutical companies worldwide to integrate their labs with their enterprise digital ecosystems. Find out how LabVantage’s informatics platform, complete with AI-powered, self-service analytics, is making a difference across the pharmaceutical industry.
Episode 91: A New Way to Partner With Academia
September 16th 2021Dr. Michael Henderson, chief business officer of BridgeBio Pharma, and one of Pharm Exec’s 2021 Emerging Pharma Leaders, discusses how his company goes beyond the traditional “hand off” approach between academia and industry, and looks to partner with institutions early on to fill important voids in drug development.
From Lab to Life: Accelerating End-to-End Drug Development to Bring Medicines to Patients Faster
September 13th 2021In Episode Two of the Syneos Health Dedicated Dialogue podcast series, we reveal how harnessing broad expertise across the product development lifecycle leads to relevant, effective and efficient solutions that speed commercial success and bring novel drugs to patients sooner to improve patient care.
Episode 89: Cellicon Valley Outlook
August 19th 2021Audrey Greenberg, co-founder and executive managing director of the Center for Breakthrough Medicines and Discovery Labs, discusses how cell and gene therapy has turned Philadelphia into Cellicon Valley, and how her organization is playing a role in that growth even beyond the city’s borders.